-
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
Editor’s Note: Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated…
-
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated with disease progression and prostate cancer–specific mortality. Consequently, reducing postoperative BCR and improving long-term outcomes in prostate cancer patients have become major areas of clinical research focus.
-
Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
Beijing Urologic Oncology Young Physicians Academic Exchange Meeting Editor’s Note: From January 10 to 11, 2026, the Beijing Urologic Oncology Young Physicians Academic Exchange Meeting was successfully held in Beijing.…
-
Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
A multidisciplinary team led by Professors Xuesong Li and Qi Tangfrom the Institute of Urology and Department of Urology, Peking University First Hospital, in collaboration with Professor Jianhua Zhang’s team from the Department of Nuclear Medicine and Professor Xiaoying Li’s team from the Department of Radiation Oncology, has published an original research article in Clinical…
-
Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting brought together leading experts in urologic oncology from China and around the world to engage in in-depth discussions on advances in the diagnosis and treatment of urothelial carcinoma, prostate cancer, renal cell carcinoma, and other major genitourinary malignancies.
-
2025 Tianjin International Breast Cancer Conference | Prof. Jihui Hao: A Blueprint for Intelligent Breast Cancer Prevention and Care
Editor’s Note From December 3 to 6, the Fifth Tianjin International Breast Cancer Conference was grandly held in Tianjin. The meeting was hosted by the Chinese Anti-Cancer Association and organized…
-
2025 Tianjin International Breast Cancer Conference | Prof. Zhongsheng Tong: Targeted Therapy Frontiers and the “Tianjin Experience”
Editor’s Note Recently, the 2025 Tianjin International Breast Cancer Conference, hosted by the Chinese Anti-Cancer Association and co-organized by Tianjin Medical University Cancer Institute and Hospital together with the National…
-
2025 Yat-sen Breast Cancer Conference | Prof. Qiang Liu: Advancing Multidisciplinary Care for Breast Cancer in China
Editor’s Note The 2025 Yat-sen Breast Cancer Conference, held in conjunction with the 2025 CSCO BC Southern Forum, the Second National Conference on the Release of the Chinese Expert Consensus…
Connecting Medical Expertise through Media